All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Allogeneic cardiosphere-derived cells
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Capricor Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 12, 2021
Details:
Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Voclosporin
Therapeutic Area: Immunology Product Name: ISA247
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Aurinia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The dedicated facility will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): AdCOVID
Therapeutic Area: Infections and Infectious Diseases Product Name: AdCOVID
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Altimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2020
Details:
Altimmune's agreement with Lonza expands its current clinical and commercial manufacturing strategy for AdCOVID. AdCOVID, a single-dose intranasal vaccine for COVID-19, designed to generate a broad immune response with the unique ability to promote nasal mucosal immunity.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US). Operations are expected to start in H1 2021. AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA).
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): NILK-2301
Therapeutic Area: Oncology Product Name: NILK-2301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: LamKap Bio Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2020
Details:
Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Lenzilumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Kodiak Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 27, 2020
Details:
Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Abelacimab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Anthos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2020
Details:
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Wnt Activating Antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Surrozen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 01, 2020
Details:
Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
